Cargando…
EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
In non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation, 50%–65% of cases acquire resistance after treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) because of an EGFR T790M point mutation and 3%–14% of these cases transformed to small cell lung cancer...
Autores principales: | Sonoda, Tomoaki, Nishikawa, Shingo, Sakakibara, Rie, Saiki, Masafumi, Ariyasu, Ryo, Koyama, Junji, Kitazono, Satoru, Yanagitani, Noriko, Horiike, Atsushi, Ohyanagi, Fumiyoshi, Ninomiya, Hironori, Ishikawa, Yuichi, Nishio, Makoto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010587/ https://www.ncbi.nlm.nih.gov/pubmed/29977749 http://dx.doi.org/10.1016/j.rmcr.2018.03.009 |
Ejemplares similares
-
Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients
por: Kitazono, Satoru, et al.
Publicado: (2019) -
Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab
por: Kawashima, Yosuke, et al.
Publicado: (2019) -
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms
por: Yanagitani, Noriko, et al.
Publicado: (2020) -
Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first‐line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021‐01)
por: Uematsu, Shinya, et al.
Publicado: (2022) -
Prognostic value of (18)F‐fluoroazomycin arabinoside PET/CT in patients with advanced non‐small‐cell lung cancer
por: Saga, Tsuneo, et al.
Publicado: (2015)